About Spring Bank
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that we design to selectively target and modulate the activity of specific proteins implicated in various disease states. Our most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), is being developed for the treatment of viral diseases, including hepatitis B virus (HBV). We are developing a fixed-dose combination of inarigivir with tenofovir disoproxil fumarate for HBV. We are also developing other SMNH product candidates, including SB 11285, our lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway.
We are devoted to pioneering our proprietary Small Molecule Nucleic Acid Hybrid (SMNH) chemistry platform to discover and develop novel therapies to improve the lives of patients worldwide. We design our SMNH compounds to bind specifically to their intended proteins, producing high therapeutic benefit over current therapies. We are committed to the highest standards of scientific excellence and integrity for the benefit of patients and the medical community.
Since inception in 2002, we have sought to apply our small molecule nucleic acid hybrid (SMNH) chemistry platform toward the discovery and development of novel drugs. This work has culminated in preclinical evidence of safety and activity as well as the first SMNH compound, inarigivir, which entered human clinical studies in early 2013. In June 2016, we initiated our global Phase 2 ACHIEVE trial in chronically infected hepatitis B patients.